Ischemic Stroke is caused by an obstruction within a blood vessel that is supplying blood to the brain. This is often caused by blood clots but can also be caused by other substances like plaques. The gold standard treatment for strokes for many years has been the administration of clot dissolving or clot busting medication called tissue plasminogen activator (tPA). This type of drug must be administered as soon as possible, with a four hour window from symptom onset, to increase chances of recovery. A significant number of patients do not get to healthcare facilities quickly enough to meet that window and even some of those who do, later experience hemorrhagic complications from the medication. It is very effective for smaller clots but often fails to break up larger clots. Some patients cannot receive tPA, in which cases physicians rely on antiplatelet or anticoagulant medicine to ensure blood clots do not get larger.
General Report Contents
• Market Analyses include: Unit Sales, ASPs, Market Value & Growth Trends
• Market Drivers & Limiters for each chapter segment
• Competitive Analysis for each chapter segment
• Section on recent mergers & acquisitions
There will be significant market growth in the mechanical thrombectomy market over the forecast period, driven by growth in unit sales as mechanical thrombectomy is adopted as standard of care for acute ischemic stroke patients.
This market includes stent retrievers and suction thrombectomy catheters. The majority of the time a combination of the two categories is used but there a number of factors that can impact treatment decisions, one key factor being physician preference. Studies found new stent retriever devices are superior to first generation aspiration devices but there have been fewer studies comparing the second generation of both categories. There had been a strong evolution in Europe towards combination of aspiration and stent retriever but now the market is moving even farther towards aspiration only techniques. Both categories of devices have are required in specific cases as certain devices appear to more successful based on the anatomy, clot morphology and clot locations. There has been huge variability on reported success rates with aspiration-only which influences the frequency that a stent retriever is required in combination. Additional clinical trials will influence whether the devices continue to be used in conjunction or whether one category will cannibalize shares form the other.
The ASP of both categories of devices is expected to remain stable over the forecast period. The stent retriever drives the market value higher quicker due to the higher ASP it commands and the need for more than one device per procedure.
'
TABLE OF CONTENTS I
LIST OF FIGURES X
LIST OF CHARTS XII
EXECUTIVE SUMMARY 1
EUROPEAN NEUROMODULATION, NEUROVASCULAR, NEUROSURGICAL AND MONITORING DEVICE MARKET OVERVIEW 1
COMPETITIVE ANALYSIS 3
MARKET TRENDS 7
MARKET DEVELOPMENTS 10
MARKETS INCLUDED 11
PROCEDURES INCLUDED 12
KEY REPORT UPDATES 13
VERSION HISTORY 13
RESEARCH METHODOLOGY 14
1.1 RESEARCH SCOPE 14
1.2 IDATA’S 9-STEP METHODOLOGY 14
Step 1: Project Initiation & Team Selection 14
Step 2: Prepare Data Systems and Perform Secondary Research 16
Step 3: Preparation for Interviews & Questionnaire Design 17
Step 4: Performing Primary Research 18
Step 5: Research Analysis: Establishing Baseline Estimates 20
Step 6: Market Forecast and Analysis 21
Step 7: Identify Strategic Opportunities 23
Step 8: Final Review and Market Release 24
Step 9: Customer Feedback and Market Monitoring 25
DISEASE OVERVIEW 26
2.1 BASIC ANATOMY 26
2.2 DISEASE PATHOLOGY AND DISORDERS 28
2.2.1 Introduction 28
2.2.2 General Diagnostics and Neurosurgery 30
2.2.3 Tumor and Brain Cancer 32
2.2.4 Brain Arteriovenous Malformations 34
2.2.5 Ischemic Stroke 35
2.2.6 Brain Aneurysm 36
2.2.7 Disorders Related to Cerebrospinal Fluids and Intracranial Pressure 38
2.2.7.1 Hydrocephalus and Intracranial Pressure Disorder 38
2.2.7.2 Cerebral Edema 39
2.2.8 Indication for Neuromodulation 41
2.2.9 Traumatic brain injury 43
COUNTRY PROFILES 44
3.1 INTRODUCTION 44
3.1.1 Population 44
3.1.2 GDP Per Capita 44
3.1.3 Price Index 44
3.2 GERMANY 45
3.3 FRANCE 46
3.4 UNITED KINGDOM 47
3.5 ITALY 48
3.6 SPAIN 49
3.7 BENELUX 50
3.8 SCANDINAVIA 51
3.9 AUSTRIA 52
3.10 SWITZERLAND 53
3.11 PORTUGAL 54
PRODUCT ASSESSMENT 55
4.1 PRODUCT PORTFOLIOS 55
4.1.1 Mechanical Thrombectomy 55
4.1.1.1 Introduction 55
4.1.1.2 Product Matrix for Mechanical Trombectomy device: Core Companies 58
4.2 REGULATORY ISSUES AND RECALLS 59
4.2.1 Mechanical Thrombectomy 59
4.3 CLINICAL TRIALS 60
4.3.1 Mechanical Thrombectomy 60
MECHANICAL THROMBECTOMY MARKET 63
5.1 INTRODUCTION 63
5.2 MARKET OVERVIEW 65
5.3 MARKET ANALYSIS AND FORECAST 69
5.3.1 Stent Retriever Market 69
5.3.2 Thrombectomy Catheter Market 71
5.4 DRIVERS AND LIMITERS 73
5.4.1 Market Drivers 73
5.4.2 Market Limiters 74
5.5 COMPETITIVE MARKET SHARE ANALYSIS 76
ABBREVIATIONS 80
APPENDIX: COMPANY PRESS RELEASES 83
Chart 1 1: Neurological Device Market by Segment, Europe, 2013 – 2023 2
Chart 1 2: Neurological Device Market Overview, Europe, 2013 &2023 2
Chart 3 1: Country Profile, Germany, 2016 45
Chart 3 2: Country Profile, France, 2016 46
Chart 3 3: Country Profile, United Kingdom, 2016 47
Chart 3 4: Country Profile, Italy, 2016 48
Chart 3 5: Country Profile, Spain, 2016 49
Chart 3 6: Country Profile, Benelux, 2016 50
Chart 3 7: Country Profile, Scandinavia, 2016 51
Chart 3 8: Country Profile, Austria, 2016 52
Chart 3 9: Country Profile, Switzerland, 2016 53
Chart 3 10: Country Profile, Portugal, 2016 54
Chart 5 1: Mechanical Thrombectomy Market by Segment, U.S., 2013 – 2023 67
Chart 5 2: Mechanical Thrombectomy Market Breakdown, U.S., 2016 68
Chart 5 3: Mechanical Thrombectomy Market Breakdown, U.S., 2023 68
Chart 5 4: Stent Retriever Market, Europe, 2013 – 2023 70
Chart 5 5: Thrombectomy Catheter Market, Europe, 2013 – 2023 72
Chart 5 6: Leading Competitors, Mechanical Thrombectomy Market, U.S., 2016 79
Medtronic
Stryker
Codman & Shurtleff, Inc.
St. Jude Medical
Nevro
Carl Zeiss
Boston Scientific
LivaNova
Terumo MicroVention
Penumbra Inc.
Leica
Integra LifeSciences
BrainLab
Balt
Magstim
Phenox
MagVenture
Elekta
Moëller Wedel
Misonix
Sophysa
Aesculap
MAG & More
Neurosoft
Acandis
Soring
Brainsway
Nexstim
Others include: ANT, Asahi Intecc, Axonics, Blockade, Dispomedica, Enteromedics, Flowonix, Inomed, Intrapace, Kaneka Medical Products, MHT, Micrus Endovascular, MRC, Navimetric, Neuravi, Neuronetics, Neuropace, NextGen Medicla System, Nuvectra, Scientia Vascular, Spiegelberg, Stimwave, Tokai Medical Product, Tricumed, Vascular Solutions, etc.
